What Are Wall Street Analysts' Target Price for Incyte Stock?

Valued at a market cap of $14.8 billion, Incyte Corporation (INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics for oncology, inflammation, and autoimmunity areas. The Wilmington, Delaware-based company focuses on finding solutions for serious unmet medical needs. 

Shares of this biotech company have slightly underperformed the broader market over the past 52 weeks. INCY has gained 30% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 31.1%. Moreover, shares of INCY are up 12.4%, compared to SPX’s nearly 24.1% return on a YTD basis.